Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Checkpoint Inhibitors in Kidney Transplant Recipients and the Potential Risk of Rejection.

Literature DB >> 26752406

Checkpoint Inhibitors in Kidney Transplant Recipients and the Potential Risk of Rejection.

T Alhamad^1,2, K Venkatachalam¹, G P Linette³, D C Brennan¹.

Abstract

Mesh：

Substances：

Year: 2016 PMID： 26752406 DOI： 10.1111/ajt.13711

Source DB: PubMed Journal: Am J Transplant ISSN： 1600-6135 Impact factor: 8.086

Keyword Cloud
Cited

× No keyword cloud information.

36 in total

Review 1. Renal complications of immune checkpoint blockade.

Authors: Naoka Murakami; Shveta Motwani; Leonardo V Riella
Journal: Curr Probl Cancer Date: 2016-12-19 Impact factor: 3.187

2. Overall and Site-Specific Cancer Mortality in Patients on Dialysis and after Kidney Transplant.

Authors: Eric H Au; Jeremy R Chapman; Jonathan C Craig; Wai H Lim; Armando Teixeira-Pinto; Shahid Ullah; Stephen McDonald; Germaine Wong
Journal: J Am Soc Nephrol Date: 2019-02-14 Impact factor: 10.121

Review 3. Current status of alloimmunity.

Authors: Thiago J Borges; Naoka Murakami; Leonardo V Riella
Journal: Curr Opin Nephrol Hypertens Date: 2016-11 Impact factor: 2.894

4. Immune Checkpoint Inhibitors and the Risk of Allograft Rejection: A Comprehensive Analysis on an Emerging Issue.

Authors: Luis E Aguirre; Maria E Guzman; Gilberto Lopes; Judith Hurley
Journal: Oncologist Date: 2018-11-09

5. Ablation of interferon regulatory factor 4 in T cells induces "memory" of transplant tolerance that is irreversible by immune checkpoint blockade.

Authors: Hedong Zhang; Jie Wu; Dawei Zou; Xiang Xiao; Hui Yan; Xian C Li; Wenhao Chen
Journal: Am J Transplant Date: 2018-12-25 Impact factor: 8.086

6. Ablation of Transcription Factor IRF4 Promotes Transplant Acceptance by Driving Allogenic CD4⁺ T Cell Dysfunction.

Authors: Jie Wu; Hedong Zhang; Xiaomin Shi; Xiang Xiao; Yihui Fan; Laurie J Minze; Jin Wang; Rafik M Ghobrial; Jiahong Xia; Roger Sciammas; Xian C Li; Wenhao Chen
Journal: Immunity Date: 2017-12-05 Impact factor: 31.745

7. Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline.

Authors: Julie R Brahmer; Christina Lacchetti; Bryan J Schneider; Michael B Atkins; Kelly J Brassil; Jeffrey M Caterino; Ian Chau; Marc S Ernstoff; Jennifer M Gardner; Pamela Ginex; Sigrun Hallmeyer; Jennifer Holter Chakrabarty; Natasha B Leighl; Jennifer S Mammen; David F McDermott; Aung Naing; Loretta J Nastoupil; Tanyanika Phillips; Laura D Porter; Igor Puzanov; Cristina A Reichner; Bianca D Santomasso; Carole Seigel; Alexander Spira; Maria E Suarez-Almazor; Yinghong Wang; Jeffrey S Weber; Jedd D Wolchok; John A Thompson
Journal: J Clin Oncol Date: 2018-02-14 Impact factor: 44.544

Checkpoint Inhibitors in Kidney Transplant Recipients and the Potential Risk of Rejection.

Review 1. Renal complications of immune checkpoint blockade.

2. Overall and Site-Specific Cancer Mortality in Patients on Dialysis and after Kidney Transplant.

Review 3. Current status of alloimmunity.

4. Immune Checkpoint Inhibitors and the Risk of Allograft Rejection: A Comprehensive Analysis on an Emerging Issue.

5. Ablation of interferon regulatory factor 4 in T cells induces "memory" of transplant tolerance that is irreversible by immune checkpoint blockade.

6. Ablation of Transcription Factor IRF4 Promotes Transplant Acceptance by Driving Allogenic CD4⁺ T Cell Dysfunction.

7. Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline.

Review 8. Cutaneous squamous cell carcinoma in the organ transplant recipient.

Review 9. Programmed T cell differentiation: Implications for transplantation.

Review 10. Second-Line Treatment Landscape for Renal Cell Carcinoma: A Comprehensive Review.

Checkpoint Inhibitors in Kidney Transplant Recipients and the Potential Risk of Rejection.

Review 1. Renal complications of immune checkpoint blockade.

2. Overall and Site-Specific Cancer Mortality in Patients on Dialysis and after Kidney Transplant.

Review 3. Current status of alloimmunity.

4. Immune Checkpoint Inhibitors and the Risk of Allograft Rejection: A Comprehensive Analysis on an Emerging Issue.

5. Ablation of interferon regulatory factor 4 in T cells induces "memory" of transplant tolerance that is irreversible by immune checkpoint blockade.

6. Ablation of Transcription Factor IRF4 Promotes Transplant Acceptance by Driving Allogenic CD4+ T Cell Dysfunction.

7. Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline.

Review 8. Cutaneous squamous cell carcinoma in the organ transplant recipient.

Review 9. Programmed T cell differentiation: Implications for transplantation.

Review 10. Second-Line Treatment Landscape for Renal Cell Carcinoma: A Comprehensive Review.

6. Ablation of Transcription Factor IRF4 Promotes Transplant Acceptance by Driving Allogenic CD4⁺ T Cell Dysfunction.